Do Checkpoint Inhibitors Compromise the Cancer Patients’ Immunity and Increase the Vulnerability to COVID-19 Infection?

Immunotherapy - United Kingdom
doi 10.2217/imt-2020-0077
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Future Medicine Ltd

Related search

Cardiovascular Vulnerability to COVID-19 in Cancer Survivors

2020English

Hematologic Parameters in Patients With COVID‐19 Infection

American Journal of Hematology
Hematology
2020English

Early Stage Prediction of US County Vulnerability to the COVID-19 Pandemic

2020English

Caring for Patients With Cancer in the COVID-19 Era

Nature Medicine
BiochemistryMedicineGeneticsMolecular Biology
2020English

Is Nicotine Exposure Linked to Cardiopulmonary Vulnerability to COVID-19 in the General Population?

FEBS Journal
BiochemistryCell BiologyMolecular Biology
2020English

COVID-19 Infection in Children

Lancet Respiratory Medicine,The
PulmonaryRespiratory Medicine
2020English

COVID-19 Asymptomatic Infection Estimation

2020English

Should ACE Inhibitors and Angiotensin Receptor Blockers Be Withdrawn in the Current Setting of COVID-19 Infection?

Wits Journal of Clinical Medicine
2020English

Urticarial Eruption in COVID-19 Infection

Journal of the European Academy of Dermatology and Venereology
DermatologyInfectious Diseases
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy